How many insider trades does FilingIQ track for JAZZ?

FilingIQ tracks 1,169 Form 4 insider transactions for JAZZ (Jazz Pharmaceuticals plc), covering filings from Dec 5, 2014 onwards. 49 of those were filed in the last 90 days.

Are JAZZ insiders net buyers or net sellers?

Across the full Form 4 history for JAZZ, 21 transactions (2%) were open-market purchases and 577 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does JAZZ insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is JAZZ in?

Jazz Pharmaceuticals plc (JAZZ) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $10.50B.

JAZZ insider trading

NasdaqGS Healthcare

Jazz Pharmaceuticals plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,169

Last 90 days

Buys / sells

2% / 49%

Market cap

$10.50B

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Company website: www.jazzpharma.com

JAZZ insider activity at a glance

FilingIQ has scored 1,169 insider transactions for JAZZ since Dec 5, 2014. The most recent filing in our index is dated May 1, 2026.

Across the full history, 21 open-market purchases and 577 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on JAZZ insider trades is 58.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live JAZZ trades on FilingIQ Raw filings on SEC EDGAR

Latest JAZZ Form 4 filings

Patil Neena M EVP & Chief Legal Officer

S Feb 26, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding JAZZ

Rhenman & Partners Asset Management AB

$18.59M · 2.0% of AUM

Philosophy Capital Management LLC

$14.35M · 0.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for JAZZ?: FilingIQ tracks 1,169 Form 4 insider transactions for JAZZ (Jazz Pharmaceuticals plc), covering filings from Dec 5, 2014 onwards. 49 of those were filed in the last 90 days.
Are JAZZ insiders net buyers or net sellers?: Across the full Form 4 history for JAZZ, 21 transactions (2%) were open-market purchases and 577 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does JAZZ insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is JAZZ in?: Jazz Pharmaceuticals plc (JAZZ) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $10.50B.

Methodology & sources

Every JAZZ insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.